Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.
Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), with empagliflozin and mineralocorticoid receptor antagonists (MRA) showing promise, noted Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.
Transcript
What are your thoughts on a combination regimen for HFpEF that contains empagliflozin or an SGLT2 inhibitor as the anchor drug?
I completely agree with that mindset. That mindset we had, and we were successful in HFrEF, so nobody questioned what is the drug for HFrEF to give combination therapy. And if you now look at this, we now have data with empagliflozin for EF [ejection fraction] all the way up to 65%. We'll see what happens above 65% soon, but we know that valsartan/sacubitril with median EF of less than 57% showed benefit. If you exclude the Russia/Georgia data from TOPCAT and all the heterogeneity that we saw, MRA seems to be benefiting as well. And now, obviously, we have HFpEF trials going on with MRA.
I would say that the HFpEF treatment, or at least a segment of HFpEF treatment, will start looking very much like HFrEF. But certainly, with EMPEROR-Preserved, empagliflozin all the way up to 65% is pretty much a straightforward answer.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More